Zdrowie i gospodarka · 17/06/2024
FDA Releases Final Guidance for Oligonucleotide Therapeutics Development
The FDA has released a final guidance document outlining clinical pharmacology considerations for the development of oligonucleotide therapeutics, addressing factors such as QT interval prolongation, immunogenicity risk assessment, and drug-drug interactions.